The American Journal of Medicine
Volume 119, Issue 5, Supplement 1 , Pages S40-S47 , May 2006

Prevention of Loss of Renal Function Over Time in Patients with Diabetic Nephropathy

  • Anthony Barnett, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Anthony Barnett, MD, Division of Medical Sciences, University of Birmingham and Birmingham Heartlands and Solihull National Health Service Trust, Birmingham B9 5SS, United Kingdom.

References 

  1. Mogensen CE . Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment . Scand J Clin Lab Invest . 1976;36:383–388
  2. Parving HH , Smidt UM , Friisberg B , et al.   A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy . Diabetologia . 1981;20:457–461
  3. Schmitz A , Vaeth M . Microalbuminuria: a major risk factor in non–insulin-dependent diabetes: a 10-year follow-up study of 503 patients . Diabet Med . 1988;5:126–134
  4. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Heath, National Institute of Diabetes and Digestive and Kidney Diseases; 2004. NIH Publication No. 26-5-2005. Available at: http://www.usrds.org/adr_2004.htm. Accessed February 28, 2006.
  5. Raine AE . Epidemiology, development, and treatment of end-stage renal failure in type 2 (non–insulin-dependent) diabetic patients in Europe . Diabetologia . 1993;36:1099–1104
  6. Parving HH , Andersen S , Jacobsen P , et al.   Angiotensin receptor blockers in diabetic nephropathy (renal and cardiovascular end points) . Semin Nephrol . 2004;24:147–157
  7. Parving HH , Hommel E . Prognosis in diabetic nephropathy . BMJ . 1989;299:230–233
  8. Mogensen CE . Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy . BMJ . 1982;285:685–688
  9. Parving HH , Andersen AR , Smidt UM , Svendsen PA . Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy . Lancet . 1983;1:1175–1179
  10. Lewis EJ , Hunsicker LG , Bain RP , et al.   The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy . N Engl J Med . 1993;329:1456–1462
  11. Ravid M , Savin H , Jutrin I , et al.   Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients . Ann Intern Med . 1993;118:577–581
  12. Parving HH , Lehnert H , Bröchner-Mortensen J , et al.   The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes . N Engl J Med . 2001;345:870–878
  13. Barnett AH , Bain SC , Bouter P , et al.   Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy . N Engl J Med . 2004;351:1952–1961
  14. Wolf G . Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics . Nephrol Dial Transplant . 1998;13:1131–1142
  15. Unger T , Culman J , Gohlke P . Angiotensin II receptor blockade and end-organ protection (pharmacological rationale and evidence) . J Hypertens . 1998;16(suppl 7):S3–S9
  16. Timmermans PB , Duncia JV , Carini DJ , et al.   Discovery of losartan, the first angiotensin II receptor antagonist . J Hum Hypertens . 1995;9(suppl 5):S3–S18
  17. Brenner BM . The history and future of renoprotection . Kidney Int . 2003;64:1163–1168
  18. Modlinger PS , Wilcox CS , Aslam S . Nitric oxide, oxidative stress, and progression of chronic renal failure . Semin Nephrol . 2004;24:354–365
  19. Wolf G . Angiotensin II as a mediator of tubulointerstitial injury . Nephrol Dial Transplant . 2000;15(suppl 6):61–63
  20. Dunn MJ . Prostaglandins, angiotension II, and proteinuria . Nephron . 1990;55(suppl 1):30–37
  21. Melchior WR , Bindlish V , Jaber LA . Angiotensin-converting enzyme inhibitors in diabetic nephropathy . Ann Pharmacother . 1993;27:344–350
  22. Price DA , Lansang MC , Osei SY , et al.   Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan . Diabet Med . 2002;19:858–861
  23. Sasaki M , Uehara S , Ohta H , et al.   Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice . Life Sci . 2004;75:869–880
  24. Gross O , Schulze-Lohoff E , Koepke ML , et al.   Antifibrotic, nephroprotective potential of ACE inhibitor vs. AT1 antagonist in a murine model of renal fibrosis . Nephrol Dial Transplant . 2004;19:1716–1723
  25. Nakamura T , Obata J , Kimura H , et al.   Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis . Kidney Int . 1999;55:877–889
  26. Ahmad J , Shafique S , Abidi SM , Parwez I . Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects . Diabetes Res Clin Pract . 2003;60:131–138
  27. Nankervis A , Nicholls K , Kilmartin G , et al.   Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria (a 3-year placebo-controlled biopsy study) . Metabolism . 1998;47(suppl 1):12–15
  28. Brewster UC , Perazella MA . The renin-angiotensin-aldosterone system and the kidney (effects on kidney disease) . Am J Med . 2004;116:263–272
  29. Chung O , Unger T . Unopposed stimulation of the angiotensin AT2 receptor in the kidney . Nephrol Dial Transplant . 1998;13:537–540
  30. Amerena J , Pappas S , Ouellet J-P . ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension . J Int Med Res . 2002;30:543–552
  31. Smith DHG , Neutel JM , Morgenstern P . Once-daily telmisartan compared with enalapril in the treatment of hypertension . Adv Ther . 1998;15:229–240
  32. Karlberg BE , Lins L-E , Hermansson K  TEES Study Group . Efficacy and safety of telmisartan, a selective AT1-receptor antagonist, compared with enalapril in elderly patients with primary hypertension . J Hypertens . 1999;17:293–302
  33. Neutel JM , Smith DHG , Reilly PA . The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension . Int J Clin Pract . 1999;53:175–178
  34. Hannedouche T , Chanard J , Baumelou B  French Collaborative Telmisartan Study Group . Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension . J Renin Angiotensin Aldosterone Syst . 2001;2:246–254
  35. Ramsay LE , Kirwan BA  Telmisartan Study Group (THESI) . A comparison of cough in hypertensive patients receiving telmisartan, enalapril, or hydrochlorothiazide [poster] . J Hypertens . 1998;16(suppl 2):S241
  36. Kidney Disease Outcomes Quality Initiative (K/DOQI) . K-DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease . Am J Kidney Dis . 2004;43(suppl 1):S1–S290
  37. Brenner BM , Cooper ME , de Zeeuw D , et al.   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . N Engl J Med . 2001;345:861–869
  38. Lewis EJ , Hunsicker LG , Clarke WR , et al.   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med . 2001;345:851–860
  39. Bakris GL , Weir M . ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes (what’s the evidence?) . J Clin Hypertens . 2002;4:420–423
  40. Cupisti A , Rizza GM , D’Alessandro C , et al.   Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients . Biomed Pharmacother . 2003;57:169–172
  41. Redon J , Luque-Otero M , Martell N , et al.   Renin-angiotensin system gene polymorphisms (relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients) . Phamacogenomics J . 2005;5:14–20
  42. Vogt L , Navis G , Köster JE , et al.   The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension (a sub-study from the ARAMIS study) . J Hypertens . 2005;23:2055–2061
  43. Estacio RO , Jeffers BW , Gifford N , Schrier RW . Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes . Diabetes Care . 2000;23(suppl 2):B54–B64
  44. Lacourcière Y , Belanger A , Godin C , et al.   Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy . Kidney Int . 2000;58:762–769
  45. MacIsaac RJ , Tsalamandris C , Panagiotopoulos S , et al.   Nonalbuminuric renal insufficiency in type 2 diabetes . Diabetes Care . 2004;27:195–200
  46. Rippin J , Bain SC , Barnett AH . Rationale and design of Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study . J Diabetes Complications . 2002;16:195–200
  47. Valmadrid CT , Klein R , Moss SE , Klein BE . The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus . Arch Intern Med . 2000;160:1093–1100
  48. National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease (evaluation, classification, and stratification) . Am J Kidney Dis . 2002;39(suppl 1):S1–S266
  49. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus (results of the HOPE study and MICRO-HOPE substudy) . Lancet . 2000;355:253–259
  50. Dahlöf B , Devereux RB , Kjeldsen SE , et al.   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (a randomised trial against atenolol) . Lancet . 2002;359:995–1003
  51. Esposti LD , Di Martino M , Saragoni S , et al.   Pharmacoeconomics of antihypertensive drug treatment (an analysis of how long patients remain on various antihypertensive therapies) . J Clin Hypertens . 2004;6:76–84

PII: S0002-9343(06)00104-5

doi: 10.1016/j.amjmed.2006.01.013

The American Journal of Medicine
Volume 119, Issue 5, Supplement 1 , Pages S40-S47 , May 2006

Article Tools

* Image Usage & Resolution